Effects of Anlotinib hydrochloride combined with TP chemotherapy regimen in treatment of patients with advanced esophageal cancer
Objective:To observe effects of Anlotinib hydrochloride combined with TP chemotherapy in treatment of patients with advanced esophageal cancer.Methods:A prospective study was conducted on 62 patients with advanced esophageal cancer admitted to the hospital from February 2020 to January 2022.They were divided into control group(n=31)and study group(n=31)by using the random number table method.The control group was treated with TP chemotherapy regimen,while the study group was treated with Anlotinib hydrochloride on the basis of that of the control group.The clinical efficacy,the levels of tumor markers[carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF)]and T cell subsets(CD3+,CD4+,CD8+)before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease remission rate of the study group was 77.42%(24/31),which was higher than 48.39%(15/31)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CA125,CEA and VEGF in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3+and CD4+in the two groups were lower than those before the treatment,but those in the study group were higher than those in the control group;the levels of CD8+in the two groups were higher than those before the treatment,but that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Anlotinib hydrochloride combined with TP chemotherapy in the treatment of the patients with advanced esophageal cancer can improve the remission rate of the disease,improve the levels of T cell subsets,and reduce the levels of tumor markers.Moreover,it is superior to single TP chemotherapy.
NETL
NSTL
万方数据
